表浅性膀胱癌辅助膀胱内化疗：每月使用阿霉素或强化使用丝裂霉素。两个连续系列的比较。

Adjuvant intravesical chemotherapy of superficial bladder cancer with monthly doxorubicin or intensive mitomycin. A comparison of two consecutive series.

作者信息

Ausfeld R, Beer M, Mühlethaler J P, Bartlome F, Widmer R, Tscholl R

出版信息

Eur Urol. 1987;13(1-2):10-4. doi: 10.1159/000472727.

Abstract

120 patients with the first occurrence of TNM stage Ta or T1 bladder carcinoma were given adjuvant intravesical treatment in 2 consecutive series. The first 60 received doxorubicin monthly for 6 months, then on the 9th and 12th month following surgery. The second series was given mitomycin weekly for 2 months, then monthly to the end of the first year. Median follow-up is 48 months in the first series and 15 in the second. In the doxorubicin group, 28 patients had recurrences. The recurrence rate is 1.86/100 patient-months. Seventeen of these first relapses occurred within the first year. In the 'intensive' mitomycin series, where 36 patients were observed for 12 months or more, 3 relapsed. The recurrence rate to date is 0.35. The relapse-free survival probability at 12 months is 75% in the first series and 93% in the second. Treatment was stopped due to toxicity in 4 patients in the doxorubicin group and in 10 of the mitomycin group.

摘要

120例首次出现TNM分期Ta或T1期膀胱癌的患者接受了连续两个系列的辅助膀胱内治疗。前60例患者每月接受阿霉素治疗，共6个月，然后在术后第9个月和第12个月接受治疗。第二个系列患者每周接受丝裂霉素治疗，共2个月，然后每月治疗至第一年末。第一个系列的中位随访时间为48个月，第二个系列为15个月。在阿霉素组，28例患者出现复发。复发率为1.86/100患者-月。这些首次复发中的17例发生在第一年内。在“强化”丝裂霉素系列中，36例患者观察了12个月或更长时间，3例复发。迄今为止的复发率为0.35。第一个系列在12个月时的无复发生存概率为75%，第二个系列为93%。阿霉素组有4例患者因毒性反应停止治疗，丝裂霉素组有10例。